Overview of systematic reviews of Panax notoginseng saponins in treatment of acute cerebral infarction.
10.19540/j.cnki.cjcmm.20210325.501
- Author:
Liu-Ding WANG
1
;
Zhen-Min XU
2
;
Xiao LIANG
3
;
Wen-Ran QIU
3
;
Shao-Jiao LIU
2
;
Ling-Ling DAI
2
;
Ye-Fei WANG
4
;
Chun-Yan GUO
2
;
Xiang-Hua QI
5
;
Jian WANG
6
;
Yan-Bing DING
7
;
Yun-Ling ZHANG
3
;
Xing LIAO
8
Author Information
1. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
3. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
4. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China.
5. the Affiliated Hospital of Shandong University of Traditional Chinese Medicine Ji'nan 250014, China.
6. the Affiliated Hospital to Changchun University of Chinese Medicine Changchun 130021, China.
7. Chinese Medicine Hospital of Hubei Province Hubei 430074, China.
8. Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Review
- Keywords:
AMSTAR-2;
GRADE;
Panax notoginseng saponins;
acute cerebral infarction;
overview of systematic reviews
- MeSH:
Activities of Daily Living;
Cerebral Infarction/drug therapy*;
Humans;
Panax notoginseng;
Saponins;
Systematic Reviews as Topic
- From:
China Journal of Chinese Materia Medica
2021;46(12):2963-2971
- CountryChina
- Language:Chinese
-
Abstract:
To overview the systematic reviews of Panax notoginseng saponins in the treatment of acute cerebral infarction. CNKI, CBM, Wanfang, VIP, PubMed, Cochrane Library and EMbase databases were retrieved to collect the systematic reviews of the efficacy of P. notoginseng saponins in the treatment of acute cerebral infarction. The retrieval time was from the time of database establishment to January 2021. After two researchers independently screened out the literature and extracted the data, AMSTAR-2 scale was used to evaluate the methodological quality of the included systematic reviews, GRADE system was used to grade the quality of evidences of the outcome indicators, and the efficacy evaluation was summarized. A total of 5 systematic reviews were included. AMSTAR-2 evaluation results showed that 3 items were relatively complete, while 4 items had a poor overall quality. P. notoginseng saponins combined with conventional Western medicine therapy was superior to single conventional therapy in the recovery of neurological function, enhancement of the total effective rate in clinic, and improvement of activities of daily living. GRADE evaluation results showed that the quality of evidence was from low quality to very low quality. In conclusion, in the treatment of acute cerebral infarction, P. notoginseng saponins can improve the clinical efficacy, with a good safety but a not high methodological quality and a low evidence quality. It is suggested that high-quality clinical studies shall be further carried out to provide evidence-based basis for the application of P. notoginseng saponins in the treatment of acute cerebral infarction.
